Trial reportInternational journal of radiation oncology, biology, physics2018
The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.
Trial report in International journal of radiation oncology, biology, physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2023Pooled it
- Hypofractionation for clinically localized prostate cancer.The Cochrane database of systematic reviews · 2019Pooled it
- Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial.La Radiologia medica · 2023Trial
- An overlooked opportunity? SBRT + ADT for aggressive prostate cancer in the elderly.Clinical and translational radiation oncology · 2026Article
- Outcome and Toxicity of Moderately Hypofractionated Post-Prostatectomy Radiotherapy: A Retrospective Study.Medical sciences (Basel, Switzerland) · 2025Article
- Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study.Prostate cancer and prostatic diseases · 2025Article
- Post-treatment changes in bowel and urinary function in prostate cancer patients treated with moderate or ultra-hypofractionation: A prospective cohort study.Clinical and translational radiation oncology · 2025Article
- The impact of age on clinicopathological features and treatment results in patients with localised prostate cancer receiving definitive radiotherapy.Acta oncologica (Stockholm, Sweden) · 2024Article
- Physician reported toxicities and patient reported quality of life of transperineal ultrasound-guided radiotherapy of prostate cancer.Clinical and translational radiation oncology · 2024Article
- Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer.Acta oncologica (Stockholm, Sweden) · 2024Article
- RECENT ADVANCES IN RADIOTHERAPY MODALITIES FOR PROSTATE CANCER.Acta clinica Croatica · 2022Review
- Non-stereotactic radiotherapy in older cancer patients.Heliyon · 2022Review
- Personalised treatment for older adults with cancer: The role of frailty assessment.Technical innovations & patient support in radiation oncology · 2020Article
- Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer - Brachytherapy enhanced late GU toxicity especially in elderly.Clinical and translational radiation oncology · 2020Article
- Influence of the technique and comorbidities in hypofractionated radiotherapy for prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Article
- Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?Current urology reports · 2019Review
- Article
- Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- The contemporary management of prostate cancer.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 15 institutions in 1 country.
Funding
Abstract
purposeOutcome data on radiation therapy for prostate cancer in an elderly population are sparse. The CHHiP (Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer) trial provides a large, prospectively collected, contemporary dataset in which to explore outcomes by age. METHODS AND MATERIALS: CHHiP participants received 3 to 6 months of androgen deprivation therapy and were randomly assigned (1:1:1) to receive 74 Gy in 37 fractions (conventional fractionation), 60 Gy in 20 fractions, or 57 Gy in 19 fractions. Toxicity was assessed using clinician-reported outcome (CRO) and patient-reported outcome questionnaires. Participants were categorized as aged < 75 years or ≥ 75 years. Outcomes were compared by age group.
resultsOf 3216 patients, 491 (15%) were aged ≥ 75 years. There was no difference in biochemical or clinical failure rates between the groups aged < 75 years and ≥ 75 years for any of the fractionation schedules. In the group aged ≥ 75 years, biochemical or clinical failure-free rates favored hypofractionation, and at 5 years, they were 84.7% for 74 Gy, 91% for 60 Gy, and 87.7% for 57 Gy. The incidence of CRO (grade 3) acute bowel toxicity was 2% in both age groups. The incidence of grade 3 acute bladder toxicity was 8% in patients aged < 75 years and 7% in those aged ≥ 75 years. The 5-year cumulative incidence of CRO grade ≥ 2 late bowel side effects was similar in both age groups. However, in the group aged ≥ 75 years, there was a suggestion of a higher cumulative incidence of bowel bother (small or greater) with 60 Gy compared with 74 Gy and 57 Gy. Patient-reported bladder bother was slightly higher in the group aged ≥ 75 years than the group aged < 75 years, and there was a suggestion of a lower cumulative incidence of bladder bother with 57 Gy compared with 74 Gy and 60 Gy in patients aged ≥ 75 years, which was not evident in those aged < 75 years.
conclusionsHypofractionated radiation therapy appears to be well tolerated and effective in men aged ≥ 75 years. The 57-Gy schedule has potential advantages in that it may moderate long-term side effects without compromising treatment efficacy in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.